PE20250159A1 - Conjugados de neodegradador-anticuerpo anti-cd33 - Google Patents

Conjugados de neodegradador-anticuerpo anti-cd33

Info

Publication number
PE20250159A1
PE20250159A1 PE2023003198A PE2023003198A PE20250159A1 PE 20250159 A1 PE20250159 A1 PE 20250159A1 PE 2023003198 A PE2023003198 A PE 2023003198A PE 2023003198 A PE2023003198 A PE 2023003198A PE 20250159 A1 PE20250159 A1 PE 20250159A1
Authority
PE
Peru
Prior art keywords
antibody
formula
conjugates
cdr1
cdr2
Prior art date
Application number
PE2023003198A
Other languages
English (en)
Spanish (es)
Inventor
Nathan Fishkin
Peter U Park
Chen Bai
Original Assignee
Orum Therapeutics Inc
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Orum Therapeutics Inc, Bristol Myers Squibb Co filed Critical Orum Therapeutics Inc
Publication of PE20250159A1 publication Critical patent/PE20250159A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6867—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from a cell of a blood cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PE2023003198A 2021-06-03 2022-06-02 Conjugados de neodegradador-anticuerpo anti-cd33 PE20250159A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163202272P 2021-06-03 2021-06-03
US202163282588P 2021-11-23 2021-11-23
PCT/IB2022/055168 WO2022254377A1 (en) 2021-06-03 2022-06-02 Neodegrader-anti-cd33 antibody conjugates

Publications (1)

Publication Number Publication Date
PE20250159A1 true PE20250159A1 (es) 2025-01-22

Family

ID=84323935

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2023003198A PE20250159A1 (es) 2021-06-03 2022-06-02 Conjugados de neodegradador-anticuerpo anti-cd33

Country Status (12)

Country Link
US (1) US20240252671A1 (enExample)
EP (1) EP4346910A4 (enExample)
JP (1) JP2024521919A (enExample)
KR (1) KR20240042598A (enExample)
AU (1) AU2022284372A1 (enExample)
CA (1) CA3222185A1 (enExample)
CL (2) CL2023003605A1 (enExample)
CO (1) CO2023016712A2 (enExample)
IL (1) IL308812A (enExample)
MX (1) MX2023014282A (enExample)
PE (1) PE20250159A1 (enExample)
WO (1) WO2022254377A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20250090681A1 (en) * 2021-06-03 2025-03-20 Orum Therapeutics, Inc. Neodegrader conjugates
EP4527415A1 (en) * 2022-05-18 2025-03-26 Medilink Therapeutics (Suzhou) Co., Ltd. Antibody-drug conjugate containing protein degradation agent bioactive compound, method for preparing same, and use thereof
KR20250133786A (ko) * 2023-02-15 2025-09-08 씨에스피씨 메가리스 바이오파마슈티칼 씨오., 엘티디. 도마이드계 분자 접착제 유도체 및 이의 용도
WO2024222841A1 (zh) * 2023-04-27 2024-10-31 石药集团巨石生物制药有限公司 一种抗体药物偶联物
WO2024249235A1 (en) * 2023-06-01 2024-12-05 Abbvie Inc. Anti-human cd33 bet degrader antibody-drug conjugates
CN122422333A (zh) * 2023-10-17 2026-07-17 百时美施贵宝公司 Gspt1降解化合物、抗cd33抗体和抗体-药物缀合物及其用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5238936B2 (ja) * 2005-03-25 2013-07-17 ジーアイティーアール，インク． Ｇｉｔｒ結合分子およびその使用
CA2957226C (en) * 2008-10-29 2018-08-14 Celgene Corporation Isoindoline compounds for use in the treatment of cancer
KR101870555B1 (ko) * 2011-08-23 2018-06-22 로슈 글리카트 아게 T 세포 활성화 항원 및 종양 항원에 대해 특이적인 이중특이적 항체 및 이의 사용 방법
PL2822575T3 (pl) * 2012-03-03 2020-08-10 Immungene, Inc. Zmodyfikowane sposobami inżynierii cząsteczki fuzyjne przeciwciało-mutant interferonu
US20180312561A1 (en) * 2015-06-12 2018-11-01 Immungene, Inc. Focused interferon immunotherapy for treatment of cancer
CN104994263B (zh) * 2015-06-30 2016-12-28 广东欧珀移动通信有限公司 一种摄像装置及具有该摄像装置的终端
CN109152843A (zh) * 2016-05-20 2019-01-04 豪夫迈·罗氏有限公司 Protac抗体缀合物及其使用方法
US20230338564A1 (en) * 2020-03-31 2023-10-26 Orum Therapeutics, Inc. Neodegrader conjugates

Also Published As

Publication number Publication date
CL2023003605A1 (es) 2024-05-03
US20240252671A1 (en) 2024-08-01
JP2024521919A (ja) 2024-06-04
CA3222185A1 (en) 2022-12-08
AU2022284372A9 (en) 2024-01-11
CL2026000399A1 (es) 2026-03-20
TW202313022A (zh) 2023-04-01
WO2022254377A1 (en) 2022-12-08
EP4346910A1 (en) 2024-04-10
CO2023016712A2 (es) 2024-02-26
KR20240042598A (ko) 2024-04-02
MX2023014282A (es) 2024-02-27
IL308812A (en) 2024-01-01
EP4346910A4 (en) 2026-05-06
AU2022284372A1 (en) 2023-12-14

Similar Documents

Publication Publication Date Title
US11136390B2 (en) Anti-CD33 antibodies and methods of use thereof
JP2023179404A (ja) 抗ｃｄ３３抗体及びその使用方法
JP7525980B2 (ja) 抗Ｓｉｇｌｅｃ－７抗体及びその使用方法
CN115867568A (zh) 掩蔽的il-15细胞因子和其切割产物
TWI662968B (zh) 配體－細胞毒性藥物偶聯物、其製備方法及其應用
JP2023520517A (ja) マスクされたｉｌ－２サイトカイン及びその切断産物
CA3162754A1 (en) Anti-claudin antibody-drug conjugate and pharmaceutical use thereof
SG11202105566TA (en) Immune activating multispecific antigen-binding molecules and uses thereof
PE20240814A1 (es) Formulaciones estables de anticuerpos contra el receptor de muerte programada 1 (pd-1) y metodos para su uso
PE20191079A1 (es) Inmunoglobulinas y usos de estas
JP2022512830A (ja) エクテナサイジン誘導体を含む薬物抗体複合体
US12258398B2 (en) Anti-Siglec-5 antibodies and methods of use thereof
WO2018213316A1 (en) Anti-siglec-5 antibodies and methods of use thereof
AR121898A1 (es) Compuestos y métodos dirigidos a interleucina-34
EP3710485A1 (en) Anti-sez6 antibody drug conjugates and methods of use
AR129935A1 (es) Anticuerpo, enlazadores, carga activa, conjugados y aplicaciones de los mismos
PY24114686A (es) Anticuerpo monoclonal o fragmento de unión a antígeno del mismo que se une específicamente al ligando 1A (TL1A) similar al TNF, y uso del mismo
MX2023014527A (es) Terapias de combinacion para el tratamiento del cancer
TW202317088A (zh) 艾日布林衍生物的製備方法
CA3225975A1 (en) Drug conjugate of eribulin derivative
AR132196A1 (es) Conjugado bioactivo, método de preparación del mismo y uso del mismo
MX2023012779A (es) Regimenes de dosificacion de conjugados de peptido de inhibidores de topoisomerasa i.
Sundarapandiyan et al. Bispecific antibody-mediated destruction of Hodgkin’s lymphoma cells
PE20240809A1 (es) Composiciones y metodos de los anticuerpos anti-pacap
US20240173425A1 (en) Human cd33 antibodies and glucocorticoid conjugates